Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis
- Edwin Rietveld1,2,3,
- Ewout W Steyerberg3,
- Johan J Polder3,4,
- Henk J Veeze5,
- Yvonne Vergouwe3,
- Marianne WA Huysman6,
- Ronald de Groot2,
- Henriëtte A Moll1
- 1Division of General Pediatrics, Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, the Netherlands
- 2Division of Infectious Diseases and Immunology, Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, the Netherlands
- 3Department of Public Health, Erasmus MC, Rotterdam, the Netherlands
- 4Tranzo, Tilburg University, the Netherlands
- 5Department of Pediatrics, IJsselland Hospital, Capelleaan den IJssel, the Netherlands
- 6Division of Neonatology, Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, the Netherlands
- Correspondence to Henriëtte A Moll, Erasmus MC-Sophia, PO Box 2060, Rotterdam 3000 CB, the Netherlands;
- Accepted 17 December 2009
- Published Online First 26 May 2010
Aim The cost-effectiveness of passive immunisation against respiratory syncytial virus (RSV) in the Netherlands was studied by assessing incremental costs to prevent one hospitalisation in high-risk children using a novel individualised monthly approach.
Methods Cost-effectiveness analysis was performed by combining estimates of individual hospitalisation costs and monthly hospitalisation risks, with immunisation costs, parental costs and efficacy of passive immunisation for a reference case with the highest hospitalisation risks and costs of hospitalisation during the RSV season (male, gestational age ≤28 weeks, birth weight ≤2500 g, having bronchopulmonary dysplasia (BPD), aged 0 months at the beginning of the season (October)). Various sensitivity analyses and a cost-neutrality analysis were performed.
Results Cost-effectiveness of passive immunisation varied widely by child characteristics and seasonal month. For the reference case it was most cost effective in December at €13 190 per hospitalisation averted. Cost-effectiveness was most sensitive to changes in hospitalisation risk. For the reference case, cost neutrality was reached in December, if acquisition costs of passive immunisation decreased from €930 to €375, monthly hospitalisation risk increased from 7.6% to 17%, or hospitalisation costs increased from €10 250 to €23 250 per hospitalisation. Even if passive immunisation prevented all hospitalisations, costs per hospitalisation averted in December would still exceed €2645.
Conclusions Although cost-effectiveness of passive immunisation varied strongly by child characteristics and seasonal month, incremental costs per hospitalisation averted were always high. A restrictive immunisation policy only immunising children with BPD in high-risk months is therefore recommended. The costs of passive immunisation would have to be considerably reduced to achieve cost-effectiveness.
Funding This project is supported by The Health Care Insurance Council of the Netherlands (project number: OG99-021). The council had no involvement in study design, data collection, analysis and interpretation, writing of the report or decision to submit the paper for publication.
Competing interests None.
Ethics approval The institutional review board of the Erasmus MC approved the study.
Provenance and peer review Not commissioned; externally peer reviewed.